NZ241659A - 4-pyrimidinone derivatives and pharmaceutical compositions - Google Patents

4-pyrimidinone derivatives and pharmaceutical compositions

Info

Publication number
NZ241659A
NZ241659A NZ241659A NZ24165992A NZ241659A NZ 241659 A NZ241659 A NZ 241659A NZ 241659 A NZ241659 A NZ 241659A NZ 24165992 A NZ24165992 A NZ 24165992A NZ 241659 A NZ241659 A NZ 241659A
Authority
NZ
New Zealand
Prior art keywords
alkyl
optionally substituted
ring
branched
linear
Prior art date
Application number
NZ241659A
Inventor
Christian Hoornaert
Marc Daumas
Michel Aletru
Jean-Claude Muller
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of NZ241659A publication Critical patent/NZ241659A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Liquid Developers In Electrophotography (AREA)

Abstract

1. Compounds, existing in three tautomeric forms, corresponding to the general formulae (I), (I') and (I'') <IMAGE> in which R1 = linear or branched (C1-7)alkyl, linear or branched (C3-9)alkenyl, cyclo(C3-7)alkyl(C1-6)alkyl, R2 = H, linear or branched (C1-7)alkyl, cyclo(C3-7)alkyl(C1-3)alkyl, aryl(C1-3)alkyl optionally substituted in the ring, aryloxy(C1-3)alkyl optionally substituted in the ring, arylthio(C1-3)alkyl optionally substituted in the ring, arylsulphonyl(C1-3)alkyl optionally substituted in the ring, heteroaryl(C1-3)alkyl optionally substituted in the ring, R3 = CO2H 1H-tetrazol-5-yl, NHCOR11, NHSO2R11, CONHSO2R11, CONHOR12, where R11 = CH3, CF3 or optionally substituted phenyl, R12 = H, CH3 or optionally substituted phenyl, as well as their pharmaceutically acceptable organic or inorganic salts. Therapeutic application.t
NZ241659A 1991-02-20 1992-02-19 4-pyrimidinone derivatives and pharmaceutical compositions NZ241659A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9102032A FR2672892B1 (en) 1991-02-20 1991-02-20 DERIVATIVES OF 4-PYRIMIDINONES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.

Publications (1)

Publication Number Publication Date
NZ241659A true NZ241659A (en) 1993-03-26

Family

ID=9409925

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ241659A NZ241659A (en) 1991-02-20 1992-02-19 4-pyrimidinone derivatives and pharmaceutical compositions

Country Status (23)

Country Link
EP (1) EP0500409B1 (en)
JP (1) JP2529798B2 (en)
KR (1) KR920016434A (en)
CN (1) CN1034171C (en)
AT (1) ATE135695T1 (en)
AU (1) AU650319B2 (en)
CA (1) CA2061456A1 (en)
CS (1) CS49092A3 (en)
DE (1) DE69209113T2 (en)
DK (1) DK0500409T3 (en)
ES (1) ES2086090T3 (en)
FI (1) FI920720A (en)
FR (1) FR2672892B1 (en)
GR (1) GR3019404T3 (en)
HU (2) HUT60477A (en)
IE (1) IE76145B1 (en)
IL (1) IL101014A (en)
MX (1) MX9200690A (en)
NO (1) NO920648L (en)
NZ (1) NZ241659A (en)
PL (1) PL168617B1 (en)
RU (1) RU2073675C1 (en)
ZA (1) ZA921203B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354766A (en) * 1991-06-27 1994-10-11 Takeda Chemical Industries, Ltd. Compound and salts thereof which antagonize angiotensin II

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700543B1 (en) * 1993-01-15 1995-03-17 Synthelabo Salts of 4-pyrimidinone derivatives, their preparation and their therapeutic use.
SE9903028D0 (en) 1999-08-27 1999-08-27 Astra Ab New use
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (en) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
UY32409A (en) * 2009-01-30 2010-08-31 Takeda Pharmaceutical FUSIONED RING COMPOUND AND ITS USE
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
KR0163595B1 (en) * 1989-06-30 1998-12-01 미리암디, 메코너헤이 Substituted imidazoles
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0424317A3 (en) * 1989-10-19 1991-09-25 Ciba-Geigy Ag Pyrimidines
EP0435827A3 (en) * 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
JPH05505609A (en) * 1990-03-30 1993-08-19 メルク・エンド・カムパニー・インコーポレーテツド Substituted pyrimidines, pyrimidinones and pyridrimidines
IE912114A1 (en) * 1990-07-02 1992-01-15 Union Pharma Scient Appl Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354766A (en) * 1991-06-27 1994-10-11 Takeda Chemical Industries, Ltd. Compound and salts thereof which antagonize angiotensin II
US5583141A (en) * 1991-06-27 1996-12-10 Takeda Chemical Industries, Ltd. Heterocyclic compounds and their use as angiotensin antagonists
US5736555A (en) * 1991-06-27 1998-04-07 Takeda Chemical Industries, Ltd. Heterocyclic compounds and their use as angiotensin antagonists
US5883111A (en) * 1991-06-27 1999-03-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds and their use as angiotensin antagonists
US6100252A (en) * 1991-06-27 2000-08-08 Takeda Chemical Industries, Ltd. Heterocyclic compounds and their use as angiotensin antagonists

Also Published As

Publication number Publication date
IL101014A0 (en) 1992-11-15
IL101014A (en) 1996-06-18
JP2529798B2 (en) 1996-09-04
FI920720A (en) 1992-08-21
KR920016434A (en) 1992-09-24
FI920720A0 (en) 1992-02-19
FR2672892A1 (en) 1992-08-21
HUT60477A (en) 1992-09-28
CS49092A3 (en) 1992-09-16
ZA921203B (en) 1992-11-25
PL293531A1 (en) 1992-08-24
AU650319B2 (en) 1994-06-16
GR3019404T3 (en) 1996-06-30
ATE135695T1 (en) 1996-04-15
JPH04346980A (en) 1992-12-02
HU9200532D0 (en) 1992-05-28
IE76145B1 (en) 1997-10-08
CN1034171C (en) 1997-03-05
HU211886A9 (en) 1995-12-28
CA2061456A1 (en) 1992-08-21
CN1064269A (en) 1992-09-09
EP0500409B1 (en) 1996-03-20
FR2672892B1 (en) 1994-01-14
MX9200690A (en) 1992-08-01
DE69209113D1 (en) 1996-04-25
PL168617B1 (en) 1996-03-29
NO920648L (en) 1992-08-21
DK0500409T3 (en) 1996-07-15
EP0500409A1 (en) 1992-08-26
IE920525A1 (en) 1992-08-26
NO920648D0 (en) 1992-02-19
DE69209113T2 (en) 1996-10-31
AU1105992A (en) 1992-08-27
RU2073675C1 (en) 1997-02-20
ES2086090T3 (en) 1996-06-16

Similar Documents

Publication Publication Date Title
NZ241659A (en) 4-pyrimidinone derivatives and pharmaceutical compositions
DE69320734D1 (en) 3- (Hydroxybenzylidenyl) indolin-2-one and medicines containing the same
ATE146186T1 (en) TRIFLUOROMETHYL KETONE PEPTIDE DERIVATIVES WITH HLE-INHIBITING ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
NZ244892A (en) 6-(1h-imidazol-1-ylmethyl)-2-phenylquinoline derivatives and pharmaceutical compositions
IE902182L (en) Tricyclic compounds; pharmaceutical compositions
ATE34753T1 (en) DERIVATIVES OF PRISTINAMYCIN IIB, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS.
ATE121621T1 (en) USE OF TETRAHYDROTHIENOPYRIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS.
DE69410509D1 (en) Benzoxazine derivatives, their preparation and their use in therapy
ATE166875T1 (en) ELLIPTICINE DERIVATIVES WITH ANTI-TUMOR EFFECT
IL98454A0 (en) Derivatives of 2-aminoalkyl-5-arylalkyl-1,3-dioxanes,their preparation and their therapeutic application
ES2190941T3 (en) DERIVATIVES OF BENCILAMINODIACETAMIDAS, COMPOSITIONS, COMPOSITIONS THAT INCLUDE THEM, PREPARATION PROCEDURE AND USE.
NO922523L (en) AMINOPYRIMIDINE CARBOXAMIDE DERIVATIVES WITH THERAPEUTIC EFFECT
DE69301639D1 (en) Tetrahydronaphthalene derivatives, their preparation and their therapeutic use
DE69420179D1 (en) 2-aminopyrazine-5-carboxamide derivatives, their preparation and their use as medicines
ATE117682T1 (en) SUBSTITUTED BENZOTHIAZOLINONES, THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.